Costs about 1.2 billion to develop an approved drug...AVEO price way too low
Being that it costs about 1.2 billion to develop drug, and tivizanib is a lock for approval based on the previous drugs trial results, with a longer OS than any other trial, dont see why a bigger drug company wouldn't just buy out AVEO, rather than launch their own. If they spent less than 1.2 billion, its cheaper and much lower risk. Thats $20+ /share.
Do you think Astellas is considering it? If I recall from my reading, there are total potential milestones of +$1bb. Would think that would be reason enough, especially given the low market cap now. We'll see.